Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 40, Issue 6, 2001, Pages 658-665

  King, Bryan H ^a,i   Mark Wright, D ^b   Handen, Benjamin L ^d   Sikich, Linmarie ^e   Zimmerman, Andrew W ^f   McMahon, William ^g   Cantwell, Erin ^c   Davanzo, Pablo A ^c   Dourish, Colin T ^b   Dykens, Elisabeth M ^c   Hooper, Stephen R ^e   Jaselskis, Catherine A ^h   Leventhal, Bennett L ^h   Levitt, Jennifer ^c   Lord, Catherine ^h   Lubetsky, Martin J ^d   Myers, Scott M ^f   Ozonoff, Sally ^g   Shah, Bhavik G ^c   Snape, Michael ^b   Shernoff, Elisa W ^j   Williamson, Kwanna ^e   Cook Jr , Edwin H ^h   more..

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b Vernalis PLC   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f KENNEDY KRIEGER INSTITUTE   (United States)

^g UNIVERSITY OF UTAH   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^j NONE

more..

Author keywords

Hyperactivity; Irritability; N methyl D aspartate (NMDA); Placebo

Indexed keywords

AMANTADINE; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; AUTISM; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERACTIVITY; INSOMNIA; IRRITABILITY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 14344267755     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004583-200106000-00010     Document Type: Article

References (36)

1. Aman MG, Burrow WH, Wolford PL (1995), The Aberrant Behavior Checklist-Community: factor validity and effect of subject variables for adults in group homes. Am J Ment Retard 100:283-292
2. Aman MG, Singh NN, Stewart AW, Field CJ (1985), The Aberrant Behavior Checklist. Am J Ment Defic 89:492-502
3. Bauman M, Kemper TL (1994), Neuroanatomic observations of the brain in autism. In: The Neurobiology of Autism, Bauman ML, Kemper TL, eds. Baltimore: Johns Hopkins University Press, pp 119-145
4. Belsito KM, Kirk KS, Landa RJ, Law PA, Zimmerman AW (1998), Lamotrigine therapy for childhood autism: a randomized, double-blind, placebo-controlled trial. Neurology 50:A85
5. Birmaher B, Quintana H, Greenhill LL (1988), Methylphenidate treatment of hyperactive autistic children. J Am Acad Child Adolesc Psychiatry 27:248-251
6. Blue ME, Naidu S, Johnston MV (1999), Development of amino acid receptors in frontal cortex from girls with Rett syndrome. Ann Neurol 45:541-545
7. Campbell M, Anderson LT, Small AM, Perry R, Green W, Caplan R (1982), The effects of haloperidol on learning and behavior in autistic children. J Autism Dev Disord 12:167-175
8. Campbell M, Fish B, Shapiro DR, Collins P, Koch C (1972), Response to triiodothyronine and dextroamphetamine: a study of preschool, schizophrenic children. J Autism Child Schizophr 2:343-358
9. Campbell M, Small AM, Collins PJ, Friedman E, David R, Genieser M (1976), Levodopa and levoamphetamine: a crossover study in young schizophrenic children. Curr Ther Res Clin Exp 19:70-86
10. Chandler M, Barnhill L, Gualtieri CT (1991), Amantadine: profile of use in the developmentally disabled. In: Mental Retardation: Developing Pharmacotherapies, Ratey JJ, ed. Washington, DC: American Psychiatric Press, pp 139-162
11. Elliot CD (1990), Differential Abilities Scale (DAS). San Antonio, TX: Psychological Corporation
12. Gualtieri T, Chandler M, Coons TB, Brown LT (1989), Amantadine: a new clinical profile for traumatic brain injury. Clin Neuropharmacol 12:258-270
13. Hamberger A, Gillberg C, Palm A, Hagberg B (1992), Elevated CSF glutamate in Rett syndrome. Neuropediatrics 23:212-213
14. Ikonomidou C, Mosinger JL, Shahid Salles K, Labruyere J, OlneyJW (1989), Sensitivity of the developing rat brain to hyperbaric/ischemic damage parallels sensitivity to N-methyl-D-aspartate neurotoxicity. J Neurosci 9:2809-2818
15. Javitt DC, Zukin SR (1991), Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308
16. Johnston MV, Hohmann C, Blue ME (1995), Neurobiology of Rett syndrome. Neuropediatrics 26:119-122
17. King BH, Wright DM, Snape M, Dourish CT (2001), Case series: amantadine open-label treatment of impulsive and aggressive behavior in hospitalized children with developmental disabilities. J Am Acad Child Adolesc Psychiatry 40:654-657
18. Kornhuber J, Weller M, Schoppmeyer K, Riedereer P (1994), Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 14:91-104
19. Lappalainen R, Riikonen RS (1996), High levels of cerebrospinal fluid glutamate in Rett syndrome. Pediatr Neurol 15:213-216
20. Lin S, Constantine-Paton M (1998), Suppression of sprouting: an early function of NMDA receptors in the absence of AMPA/kainate receptor activity. J Neurosci 18:3725-3737
21. Lord C, Risi S, Lambrecht L et al. (2000), The ADOS-G (Autism Diagnostic Observation Schedule-Generic): a standard measure of social and communication deficits associated with autism spectrum disorder. J Autism Dev Disord 30:205-223
22. Lord C, Rutter M, Le Couteur A (1994), Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24:659-685
23. Masters KJ (1997), Alternative medications for ADHD (letter). J Am Acad Child Adolesc Psychiatry 36:301
24. Mattes J (1980), A pilot trial of amantadine in hyperactive children. Psychopharmacol Bull 16:67-69
25. McDonald JW, Johnston MV (1990), Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res Rev 15:41-70
26. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH (1998), A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive development disorders. Arch Gen Psychiatry 55:633-641
27. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH (1996), A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53:1001-1008
28. Mullen E (1995), Mullen Scales of Early Learning. Circle Pines, MM: American Guidance Service
29. National Institute of Mental Health (1988), Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull 21:839-842
30. Olney JW (1989), Excitatory amino acids and neuropsychiatric disorders. Biol Psychiatry 26:505-525
31. Pan JW, Lane JB, Hetherington H, Percy AK (1999), Rett syndrome: 1H spectroscopic imaging at 4.1 Tesla. J Child Neurol 14:524-528
32. Quintana H, Birmaher B, Stedge D et al. (1995), Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 25:283-294
33. Rogawski MA (1993), Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol Sci 14:325-331
34. Sparrow SS, Balla DA, Cicchetti DV (1984), Survey Form Manual (Interview Edition) of the Vineland Adaptive Behavior Scales. Circle Pines, MN: American Guidance Service
35. US Food and Drug Administration (1995), COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms, 5th ed. Washington, DC: US Department of Health and Human Services
36. Wenk GL, O'Leary M, Nemeroff CB, Bissett G, Moser H, Naidu S (1993), Neurochemical alterations in Rett syndrome. Dev Brain Res 74:67-72